YPH.DU Astellas Pharma Inc
- Market cap
- -
- P/E
- 9.8x
- P/B
- 2.26x
- ROE
- 29.2%
- Dividend yield
- 141.14%
- Fundamental score
- 4.6/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is YPH.DU undervalued?
Graham numberThe Graham number of Astellas Pharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Astellas Pharma Inc fundamental analysis
20 of 22 checks passedROE 2/2
High return on equity (29.2%), above 20%.
ROA 1/1
Return on assets (15.4%) is above the industry median (3.8%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (474.1%) is above the 5-year average (20.1% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (474.1%) is above the industry median (7.9%).
Revenue Growth 2/2
Revenue grew 12.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (16.5%), 40% or less.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 60.8x against interest expense, well covered.
PE vs Market 1/1
PE (9.8x) is below the market median (18.2x).
PE vs Industry 1/1
PE (9.8x) is below the industry median (18.3x).
PBV 0/1
Price to book (2.3x) is above the industry median (2.0x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 22.1, limit 22.5).
PEG 1/1
PEG on 5-year earnings growth is 0.49, growth is cheap.
Dividend Yield 2/2
Dividend yield (4.8%) is in the top 25% of dividend payers in the market.
Dividend Stability 2/2
Dividends paid without a cut of more than 10% for 10 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 46.7%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Astellas Pharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
Astellas Pharma Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Astellas Pharma Inc annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.31T | 1.30T | 1.31T | 1.30T | 1.25T | 1.30T | 1.52T | 1.60T | 1.91T | 2.14T | 2.56T |
| Gross Profit | 991B | 1.01T | 1.01T | 1.02T | 1.00T | 1.04T | 1.23T | 1.31T | 1.56T | 1.73T | 2.07T |
| Operating Income | 263B | 216B | 246B | 246B | 136B | 131B | 132B | 18.9B | 40.2B | 380B | 741B |
| EBITDA | - | 285B | 314B | 315B | 220B | 242B | 247B | 195B | 248B | 585B | 958B |
| Net Income | 219B | 165B | 222B | 195B | 121B | 124B | 98.7B | 17.0B | 50.7B | 292B | 567B |
| EPS | 106 | 83 | 118 | 105 | 65 | 68 | 55 | 9.51 | 28 | 163 | 316 |
| Balance Sheet | |||||||||||
| Total Assets | 1.82T | 1.86T | 1.90T | 2.32T | 2.27T | 2.33T | 2.46T | 3.57T | 3.34T | 3.57T | 3.69T |
| Total Liabilities | 549B | 590B | 639B | 1.03T | 888B | 872B | 949B | 1.97T | 1.83T | 1.74T | 1.75T |
| Shareholders' Equity | 1.27T | 1.27T | 1.26T | 1.29T | 1.39T | 1.46T | 1.51T | 1.60T | 1.51T | 1.83T | 1.94T |
| Cash & Short-term Investments | 341B | 332B | 311B | 318B | 326B | 316B | 377B | 336B | 188B | 282B | 245B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 236B | 313B | 259B | 222B | 307B | 257B | 328B | 172B | 195B | 560B | 346B |
| Capital Expenditure | 48.6B | 40.3B | 52.1B | 77.9B | 77.4B | 76.4B | 88.5B | 82.5B | 57.3B | 84.6B | 233B |
| Free Cash Flow | - | 272B | 207B | 144B | 229B | 181B | 239B | 90.0B | 137B | 476B | 113B |
| Ratios | |||||||||||
| ROE | 17.2% | 13.0% | 17.7% | 15.2% | 8.7% | 8.5% | 6.5% | 1.1% | 3.4% | 15.9% | 29.2% |
| ROA | 12.0% | 8.9% | 11.7% | 8.4% | 5.3% | 5.3% | 4.0% | 0.5% | 1.5% | 8.2% | 15.4% |
| Net Profit Margin | 16.7% | 12.7% | 17.0% | 15.0% | 9.7% | 9.6% | 6.5% | 1.1% | 2.7% | 13.6% | 22.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Astellas Pharma Inc dividends
- Dividend yield
- 141.14%
- Forward dividend
- -
- Payout ratio
- 46.7%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 136B | 76 | 46.7% |
| 2025 | JPY 129B | 72 | 254.2% |
| 2024 | JPY 117B | 65 | 684.4% |
| 2023 | JPY 100B | 56 | 101.7% |
| 2022 | JPY 85.2B | 47 | 68.7% |
| 2021 | JPY 76.2B | 41 | 63.2% |
| 2020 | JPY 73.5B | 40 | 37.6% |
| 2019 | JPY 72.1B | 38 | 32.4% |
| 2018 | JPY 71.6B | 36 | 43.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Mar 27, 2014.
Who owns Astellas Pharma Inc
Ownership data of Astellas Pharma Inc is not available yet.
Astellas Pharma Inc company profile
- Company name
- Astellas Pharma Inc
- Ticker
- YPH.DU
- Exchange
- Dusseldorf Exchange
- Sector
- Other
- Industry
- Metals & Mining
- Fiscal year end
- March
- Address
- Website
- -
About Astellas Pharma Inc
There is no Profile data available for YPH.DU.